Newborn screening for sickle cell disease: Public health impact and evaluation

Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease

Volumn , Issue , 2009, Pages

  Olney, Richard S ^a  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

Author keywords

Cost effectiveness; Genetic screening; Hemoglobinopathies; Newborn hemoglobinopathy screening; Newborn screening; Public health

Indexed keywords

EID: 84940011506     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195128307.003.0022     Document Type: Chapter

References (61)

1. Lane, PA. Sickle cell disease. Pediatr Clin North Am 1996;43:639-664.
2. Bunn, HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-769.
3. Rodgers, GP. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Semin Hematol 1997;34(3 Suppl 3):2-7.
4. Davies, SC, Oni, L. Management of patients with sickle cell disease. BMJ 1997;315:656-660.
5. Olney, RS. Preventing morbidity and mortality from sickle cell disease: a public health perspective. Am J Prev Med 1999;16:116-121.
6. Serjeant GR. The role of preventive medicine in sickle cell disease. The Watson Smith lecture. J R Coll Physicians Lond 1996;30:37-41.
7. Serjeant GR. Sickle-cell disease. Lancet 1997;350:725-730.
8. Eckman, JR. Neonatal screening. In: Embury, SH, Hebbel, RP, Mohandas, N, Steinberg, MH (eds). Sickle cell disease: basic principles and clinical practice. New York:Raven Press, 1994, pp. 509-515.
9. Serjeant GR. Sickle cell disease (2nd ed). New York: Oxford University Press, 1992, pp. 39-53.
10. Therrell, BL, Pass, KA. Hemoglobinopathy screening laboratory techniques for newborns. In: Therrell, BL (ed). Laboratory methods for neonatal screening. Washington, DC: American Public Health Association, 1993, pp. 169-189.
11. Wethers, D, Pearson, H, Gaston, M, et al. Newborn screening for sickle cell disease and other hemoglobinopathies. Pediatrics 1989;83(5 Pt 2):813-914.
12. Pearson, HA. Neonatal testing for sickle cell diseases a historical and personal review. Pediatrics 1989;83(5 Pt 2):815-818.
13. Grover, R. Newborn screening in New York City. Pediatrics 1989;83(5 Pt 2):819-822.
14. Newborn Screening Committee. The Council of Regional Networks for Genetic Services (CORN). National Newborn Screening Report 1993. Atlanta, GA: CORN, 1998:16,156-160,169.
15. National Sickle Cell Anemia Control Act. Pub. L. No. 92-294, 86 Stat. 138 (May 16,1972).
16. Wethers, D, Pearson, H, Gaston, M. Newborn screening for sickle cell disease and other hemoglobinopathies. Pediatrics 1989;83(5 Pt 2):813-814.
17. Gaston, MH, Verter, JI, Woods, G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 1986;314:1593-1599.
18. Andrews, LB, Fullarton, JE, Holtzman, NA, Motulsky, AG (eds). Assessing genetic risks: implication for health and social policy. Washington, DC: National Academy Press, 1994, p. 40.
19. John, AB, Ramlal, A, Jackson, H, Maude, GH, Waight Sharma, A, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. BMJ 1984;288:1567-1570.
20. Sickle Cell Disease Guideline Panel. Sickle cell disease: screening, diagnosis, management, and counseling in newborns and infants. Clinical practice guideline no. 6. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1993 (AHCPR publication no. 93-0562).
21. Consensus conference. Newborn screening for sickle cell disease and other hemoglobinopathies. JAMA 1987;258:1205-1209.
22. American Academy of Pediatrics Committee on Genetics. Health supervision for children with sickle cell diseases and their families. Pediatrics 1996;98:467-472.
23. American Academy of Pediatrics Committee on Genetics. Newborn screening fact sheets. Pediatrics 1996;98:473-501.
24. Harris, MS, Eckman, JR. Georgia's experience with newborn screening: 1981 to 1985. Pediatrics 1989;83(5 Pt 2):858-860.
25. Shafer, FE, Lorey, F, Cunningham, GC, Klumpp, C, Vichinsky, E, Lubin, B. Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. J Pediatr Hematol Oncol 1996;18:36-41.
26. Lane, PA, Eckman, JR. Cost-effectiveness of neonatal screening for sickle cell disease. J Pediatr 1992;120:162-163.
27. Tsevat, J, Wong, JB, Pauker, SG, Steinberg, MH. Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr 1991;118(4 Pt l):546-554.
28. Gessner, BD,Teutsch, SM, Shaffer, PA. A cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems. Early Hum Dev 1996;45:257-275.
29. Sprinkle, RH, Hynes, DM, Konrad, TR. Is universal hemoglobinopathy screening costeffective? Arch Pediatr Adolesc Med 1994;148:461-469.
30. Khoury, MJ, Genetics Working Group. From genes to public health: the applications of genetic technology in disease prevention. Am J Public Health 1996;86:1717-1722.
31. Gordis, L. The scope of screening. J Med Screen 1994;1:98-100.
32. Lorey, FW, Arnopp, J, Cunningham, GC. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol 1996;13:501-512.
33. Newborn Screening Committee. The Council of Regional Networks for Genetic Services (CORN). National Newborn Screening Report 1992. Atlanta, GA: CORN, 1995:100.
34. WHO Working Group. Community control of hereditary anaemias: memorandum from a WHO meeting. Bull World Health Organ 1983;61:63-80.
35. Grover, R, Newman, S, Wethers, D, Anyane-Yeboa, K, Pass, K. Newborn screening for hemoglobinopathies: the benefit beyond the target. Am J Public Health 1986;76:1236-1237.
36. Therrell, BL, Panny, SR, Davidson, A, et al. U.S. newborn screening system guidelines:statement of the Council of Regional Networks for Genetic Services. Screening 1992;1:135-147.
37. Haddix, AC, Teutsch, SM, Shaffer, PA (eds). Prevention effectiveness: a guide to decision analysis and economic evaluation. New York: Oxford University Press. 1996, pp. 4-5.
38. Davis, H, Schoendorf, KC, Gergen, PJ, Moore, RM Jr. National trends in the mortality of children with sickle cell disease, 1968 through 1992. Am J Public Health 1997;87:1317-1322.
39. Davis, H, Gergen, PJ, Moore, RM Jr. Geographic differences in mortality of young children with sickle cell disease in the United States. Public Health Rep 1997:112:52-58.
40. Yang, Q, Khoury, MJ, Mannino, D. Trends and patterns of mortality associated with birth defects and genetic diseases in the United States, 1979-1992: an analysis of multiple-cause mortality data. Genet Epidemiol 1997;14:493-505.
41. Cono, J, Yang, Q, Olney, RS, Khoury, MJ. Trends in sickle cell disease mortality among African-Americans, United States, 1979-1992: an analysis using multiple-cause mortality data. Proceedings of the 3rd Joint Clinical Genetics Meeting, Mar 11-14; 1996. San Antonio, TX, p. 140.
42. Leikin, SL, Gallagher, D, Kinney, TR, Sloane, D, Klug, P, Rida, W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989;84:500-508.
43. Gill, FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995;86:776-783.
44. Lee, A, Thomas, P, Cupidore, L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ 1995:311:1600-1602.
45. Emond, AM, Collis, R, Darvill, D, Higgs, DR, Maude, GH, Serjeant GR. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr 1985;107:201-206.
46. Vichinsky, E, Hurst, D, Earles, A, Kleman, K, Lubin, B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988;81:749-755.
47. Centers for Disease Control and Prevention. Mortality among children with sickle cell disease identified by newborn screening during 1990-1994 California, Illinois, and New York. MMWR 1998;47:169-172.
48. Wilimas, JA, Flynn, PM, Harris, S, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med 1993;329:472-476.
49. Davis, H, Moore, RM Jr., Gergen, PJ. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep 1997;112:40-43.
50. Yoon, PW, Olney, RS, Khoury, MJ, Sappenfield, WM, Chavez, GF, Taylor, D. Contribution of birth defects and genetic diseases to pediatric hospitalizations: a population-based study. Arch Pediatr Adolesc Med 1997;151:1096-1103.
51. Gill, FM, Brown, A, Gallagher, D, et al. Newborn experience in the Cooperative Study of Sickle Cell Disease. Pediatrics 1989;83(5 Pt 2):827-829.
52. Panny, S. Utilization of surveillance data and programs for services, education, and outreach. Proceedings of the 1st Annual National Birth Defects Prevention Workshop, December 7-8,1997, Atlanta, GA.
53. New Jersey Department of Health and Senior Services. Long-term tracking of children with sickle cell disease and other hemoglobinopathies. Trenton: New Jersey Department of Health and Senior Services, Division of Family Health Services, Special Child and Adult Health Services, 1997.
54. Eckman, J. Newborn screening for sickle cell anemia in region IV. SERGG Newsletter, June 1997:5.
55. Steele, RW, Warrier, R, Unkel, PJ, et al. Colonization with antibiotic-resistant Streptococcus pneumoniae in children with sickle cell disease. J Pediatr 1996; 128: 531-535.
56. Teach, SJ, Lillis, KA, Grossi, M. Compliance with penicillin prophylaxis in patients with sickle cell disease. Arch Pediatr Adolesc Med 1998;152:274-278.
57. Centers for Disease Control and Prevention. Defining the public health impact of drugresistant Streptococcus pneumoniae: report of a working group. MMWR 1996;45(No. RR-l):l-20.
58. Illinois Administrative Code. Title 77, Chapter 1, Subchapter i, Section 661.50 (1995).
59. Cunningham G, Kohatsu N, Stratton N, Neutra R. Meeting the challenge of genetics and public health: state perspectives on program activities (California). Proceedings of the 1st Annual Conference on Genetics and Public Health, May 13-1.5, 1998, Atlanta, GA, pp. 50-51.
60. Platt, OS, Guinan, EC Bone marrow transplantation in sickle cell anemia the dilemma of choice. N Engl J Med 1996;335:426-428.
61. Schechter, AN, Rodgers, GP. Sickle cell anemia basic research reaches the clinic. N Engl J Med 1995;332:1372-1374.